PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129030
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129030
Molecular Tumor Board Solutions Market size was valued at USD 1,801.6 Million in 2025, expanding to a CAGR of 14.2% from 2026 to 2033.
The molecular tumor board (MTB) solutions market includes software platforms, clinical decision-support systems, genomic interpretation tools, data-management platforms, and related Cancer Type that enable multidisciplinary oncology teams to evaluate and manage complex cancer cases. These solutions offer thorough case assessment and individualized treatment planning by combining genomic sequencing data, pathology findings, clinical history, biomarkers, medication information, and other patient-specific data.
Molecular Tumor Board Solutions Market- Market Dynamics
Increasing adoption of precision oncology & genomic testing and need for clinical decision support are expected to propel market demand
The increasing adoption of precision oncology and comprehensive genomic profiling is a key factor driving the growth of the molecular tumor board solutions market. Gene mutations, copy-number variations, gene fusions, biomarkers, and other molecular abnormalities are among the increasingly complex datasets produced by the widespread use of next-generation sequencing (NGS) and other cutting-edge molecular diagnostic technologies. Multidisciplinary experts, including as oncologists, pathologists, molecular biologists, geneticists, bioinformaticians, and others, are frequently needed to interpret these results. By integrating and organizing molecular and clinical data and connecting genomic findings with clinical recommendations, scientific literature, targeted medicines, and pertinent clinical trials, MTB solutions facilitate this process. This makes it possible for interdisciplinary teams to have better organized, evidence-based therapy conversations. 20.8% of patients got treatments suggested by molecular tumour boards, according to a 2025 healthcare assessment of 34 research including 12,176 patients, indicating the expanding role of MTB-based techniques in cancer treatment.
Demand for digital and AI-enabled molecular tumour board solutions that can simplify case preparation, lessen administrative workload, and improve clinical interpretation is being driven by the growing volume, diversity, and complexity of oncology data. Prior to multidisciplinary conversations, traditional MTB procedures frequently need a substantial amount of time and effort to gather and examine patient records, genetic sequencing reports, pathology findings, scientific literature, therapeutic recommendations, and pertinent clinical trial data. By consolidating clinical and molecular data into a single setting, digital MTB platforms help to overcome these obstacles by facilitating quicker access to pertinent patient data and more effective case review. Data aggregation, literature and evidence retrieval, biomarker interpretation, and other tasks can be further automated by integrating AI and advanced analytics.
The Global Molecular Tumor Board Solutions Market is segmented on the basis of Component, Solution, Cancer Type, End-Use, and Region.
The market is divided into six categories based on Solution: clinical decision support, genomic data interpretation, data analytics, reporting & visualization, patient case management, and others. By solution, clinical decision support segment is anticipated to have a considerable revenue share in the market. Clinical decision-support platforms provide the digital infrastructure needed to consolidate patient data, organize and interpret molecular findings, streamline case preparation, facilitate multidisciplinary discussions, document treatment recommendations, and support ongoing patient follow-up. Roche's navify Clinical Hub for Tumor Boards, for example, provides meeting coordination, patient-list management.
Molecular Tumor Board Solutions Market- Geographical Insights
North America's robust precision oncology ecosystem, vast genomic testing infrastructure, extensive network of specialized cancer centres, and widespread adoption of digital clinical decision-support technologies all contribute to the region's dominant position in the molecular tumour board solutions market. Healthcare facilities, technological companies, and oncology-focused groups engaged in genetic interpretation, clinical informatics, and molecular tumour board services are particularly prevalent in the United States. Developed healthcare systems, cutting-edge cancer research skills, university medical centres, and the growing use of precision medicine are what propel the European market. The region's nations are focusing more on standardizing molecular tumour board procedures, enhancing the incorporation of genomic testing into regular cancer treatment, and bolstering cooperation between clinical, diagnostic, and research teams.
India Molecular Tumor Board Solutions Market- Key Insights
India's rising cancer incidence, developing precision-oncology capabilities, improving diagnostic infrastructure, and increased access to genomic testing all contribute to the country's potential as a market for molecular tumor board solutions. With businesses like MedGenome and other specialized providers supporting the adoption of genomic-based cancer assessment and individualized treatment options, the nation is also fortifying its ecosystem of molecular diagnostics and genomic testing. However, a number of obstacles, such as unequal access to sophisticated oncology and the expensive cost of complete genetic sequencing, limit market expansion. The use of MTB solutions is anticipated to grow throughout India's main cancer centers and specialist oncology networks as genomic testing becomes more widely available and digital healthcare infrastructure advances.
The molecular tumor board solutions market is highly competitive and continuously evolving, with participation from healthcare technology companies, diagnostic & genomic-testing providers, oncology software developers, academic medical centers, pharmaceutical companies, and specialized clinical decision-support firms. Market participants are differentiating themselves through advanced genomic interpretation, clinical decision support, workflow automation, electronic health record (EHR) integration, AI-enabled analytics, and seamless data management. A key competitive trend is the shift from basic digital tools for tumor board coordination toward integrated precision-oncology platforms. Patient records, genomic profiles, pathology data, therapy recommendations, scientific literature, and clinical trial data are all being integrated into a single workflow by these platforms.
In June 2025, Roche Diagnostics Japan enhanced its navify Tumor Board software to accommodate gene-panel testing for hematological malignancies, broadening the platform's molecular tumor-board capabilities beyond solid-tumor applications.
In May 2025, Tempus announced that 10 abstracts had been selected for presentation at the 2025 ASCO Annual Meeting, showcasing the company's advancements in AI-driven precision oncology and molecularly informed cancer care.